Skip to main content
. 2015 Oct 20;125(11):4269–4280. doi: 10.1172/JCI80713

Figure 7. TA effects on oHSV in a GSC orthotopic model.

Figure 7

nu/nu mice with established GBM30 gliomas were injected in tumors with either the oHSV rQNestin34.5 or the oHSV, KNE. TA (1.3 mg per kg body weight) was administered i.p. 3 times every day, starting the day before oHSV injection, and administration continued until tissue harvest. (A) oHSV titers were assayed 4 days later after oHSV injection. n = 5 for rQNestin34.5 with TA; n = 6 for other groups. The horizontal bars and the error bars correspond to average values and mean ± SD, respectively (*P < 0.05, **P < 0.01, 1-way ANOVA test). (B) Survivorship of mice with orthotopic GBM30 gliomas was followed via Kaplan-Meier analysis. Mice with mock treatment (n = 8) (white square) or treatment with the oHSV (rQNestin34.5; 500,000 PFU) stereotactically administered into 5-day-old tumors and then with i.p. vehicle (black triangle, n = 11) or TA (black circle, n = 12) 4, 5, 6, 7, and 8 days after tumor implantation were followed. P = 0.0031, control versus oHSV; P < 0.0001, control versus oHSV plus TA; P = 0.0852, oHSV versus oHSV plus TA, by log-rank test.